TONIX PHARMACEUTICALS HOLDING CORP. Amortization of Intangible Assets
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Amortization of Intangible Assets of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-05-11
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for the quarter ending 2026-03-31 was $0.00.
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for the quarter ending 2025-12-31 was $0.00.
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for the quarter ending 2025-09-30 was $0.00.
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for fiscal 2024 was $500.00K, a 4.82% increase from fiscal 2023.
- TONIX PHARMACEUTICALS HOLDING CORP. amortization of intangible assets for fiscal 2023 was $477.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | |||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $200.00K derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $200.00K derived: sum of 3 quarters · filed 2026-03-12 | $500.00K 10-K · filed 2026-03-12 | $476.00K 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $200.00K derived: sum of 2 quarters · filed 2025-11-10 | $500.00K 10-Q · filed 2025-11-10 | $476.00K 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $200.00K 10-Q · filed 2025-08-11 | $238.00K 10-Q · filed 2024-08-16 | $500.00K 10-Q · filed 2025-08-11 | $476.00K 10-Q · filed 2024-08-16 | ||||
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-12 | $238.00K 10-Q · filed 2024-05-13 | ||||||
| 2023-12-31 | $477.00K 10-K · filed 2025-03-18 | |||||||
| 2023-09-30 | $238.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |